Thursday, October 31, 2024 at 2-3pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Treatment targets are dynamic, changing with our growing understanding of a disease and the emergence of potent therapies that enhance care standards. Newer mechanisms of action have extended rigorous goal attainment including minimal disease activity (MDA) in psoriatic arthritis, clear or almost clear skin in psoriasis, and endoscopic remission in Crohn's Disease. The benefits of achieving high treatment targets are now strong enough for medical guidelines to advocate for earlier use of targeted immunomodulators for certain conditions. In budget constrained environments, payers need to understand how innovations are driving demand for newer mechanisms of action in the TIMs marketplace.

Learning Objectives

• Examine the evolution of goal-oriented therapy and how it informs treatment guidelines to enhance care standards in IBD, Dermatological, and Rheumatologic diseases.
• Understand the benefits to payers and patients by achieving treatment targets for disease activity.
• Describe the clinical rationale for early use of targeted immunomodulators. 
• List the ways in which payers can support treat-to-target strategies to improve patient outcomes.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.